Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine vs NRT for Smoking Cessation in Mongolia
NCT04126135Phase 4Completed
- Sponsor
- Loma Linda University
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of cytisinicline in nicotine dependence (2 arms), sponsored by Loma Linda University. Primary endpoint: Length of abstinence after 25 day course of Cytisine. Started Jan 2022; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04126135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126135.